Introduction
B cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the western hemisphere and accounts for 25% of all leukemias. The indolent natural course of both early stage and smoldering CLL has left many physicians with the perception that because of this 'favorable course' the disease can be ignored until the advanced stage at which time palliative therapy is indicated. 1, 2 A diverse interpretation of the clinical data on CLL regards this disease as incurable, with advanced stage patients having a median survival of 18 months to 3 years. [3] [4] [5] The majority of circulating cells are nondividing, and it has been shown that the clonal excess of B cells results from decreased cell death rather than proliferation. 6, 7 In lymphoid cells, cytolysis induced by phosphodiesterase (PDE) inhibition results from an increase in protein kinase Amediated phosphorylation of unknown lymphoid target proteins which eventually induces apoptosis. 8, 9 Cyclic AMP is catabolized within cells to 5Ј-AMP by 3Ј:5Ј cAMP-PDE. The family of PDE includes 10 classes of enzymes which are differentially expressed in diverse cell types. 10, 11 The unspecific phosphodiesterase inhibitor theophylline has been reported to induce apoptosis in B-CLL cells. 12 In addition, theophylline synergizes with chlorambucil in vitro and a phase II clinical trial suggested that this synergism may be clinically relevant. 13, 14 However, therapy with broad-spectrum PDE inhibitors such as theophylline or pentoxifylline in patients with B-CLL is limited due to side-effects partially mediated by their activity as adenosine receptor antagonists. 15 The expression of specific phosphodiesterases in B-CLL cells favors a more targeted strategy by using specific PDE inhibitors. Kim and Lerner 16 described recently that CLL cells contain transcripts for PDE 1B1, PDE 4A and PDE 4B. They further demonstrated the cAMP-dependent induction of apoptosis by the PDE 4 inhibitor rolipram in B-CLL cells. 16 New PDE 4 inhibitors have a favorable ratio of desired action and side-effects, and are under clinical investigation in phase III trials for chronic obstructive pulmonary disease and asthma, with encouraging preliminary results. 17 To evaluate the function of PDE in the pathogenesis of B-CLL and the therapeutic potency of PDE 4 inhibitors such as rolipram further in vitro investigations are needed. A clinically relevant question is, whether rolipram synergizes with currently used chemotherapy in induction of apoptosis. Combination with PDE 4 inhibitors could allow a dose reduction of toxic cytostatic drugs. The resistance to chemotherapy in B-CLL can partly be mediated by the high expression of antiapoptotic proteins such as Bcl-2 in B-CLL. If rolipram shifts the balance of pro-and anti-apoptotic members of the Bcl-2 family towards apoptosis cytotoxic agents could become more effective.
In the present study we investigated the apoptosis-inducing potency of rolipram alone and in combination with either fludarabine or mitoxantrone as determined by annexin-V/propidium iodide flow cytometric analysis and by DNA fragmentation. We studied the expression of Bcl-2 and Bcl-X expression as anti-apoptotic members and Bax expression as a pro-apoptotic member of the Bcl-2 family either by flow cytometry or by Western blot analysis. We further investigated the role of caspase activation in rolipram-induced apoptosis.
Materials and methods

Patients
Nineteen patients (13 men and six women) with B-CLL who had not received treatment for the previous 6 months with a median age of 69 years (range, 53 to 79 years) were studied. B-CLL had been diagnosed according to standard clinical and laboratory criteria. Blood sampling was approved by the local ethics committee. The median peripheral blood leukocyte count was 76 × 10 9 leukocytes/l (range, 12 to 159 × 10 9 leukocytes/l). The median ␤2-microglobulin concentration was 4 mg/l (range, 2 to 14 mg/l) and the median thymidine kinase concentration was 18 U/l (range 5 to 80 U/l) both determined as negative predictors for disease-free survival. [18] [19] [20] Leukemic cells were positive in all cases for CD5 and CD19 by flow cytometry. According to Binet's classification, 2 at the time of inclusion, seven patients were in stage A, three patients were in stage B, and nine patients were at stage C ( Table 1) .
Preparation of B-CLL cells
Mononuclear cells were isolated from peripheral blood by gradient centrifugation over Ficoll-Hypaque (Biochrom, Berlin, Germany), as described previously. 21, 22 As a modification of the protocol, the isolation was performed in tubes containing a horizontal porous filter disc over the Ficoll layer (Leucosep tubes; Greiner, Frickenhausen, Germany) in order to facilitate layering of blood. RPMI 1640 culture medium was supplemented with 2 mM L-glutamine, 10 mM Hepes buffer, 100 U/ml penicillin and 100 g/ml streptomycin (all from Sigma, Munich, Germany). The cells were suspended and were cultured immediately after isolation at a final concentration of 2.5 × 10 6 cell/ml in RPMI 1640 culture medium further supplemented with 2% heat-inactivated sterile human serum. B-CLL cells were incubated at 37°C in a humidified atmosphere containing 5% carbon dioxide.
Preparation of compounds
Rolipram (racemate of 4-[3Ј-cyclopentyloxy-4Ј-methoxyphenyl]-2-pyrrolidone, from Schering, Berlin, Germany), supplied in powder form, was dissolved in RPMI 1640 medium by vigorous vortexing. Fludarabine was obtained from Schering, chlorambucil and mitoxantrone were obtained from Lederle Laboratories (Gosport, UK). Propidium iodide (PI) was obtained from Sigma (Munich, Germany) and the pan-caspase 
Analysis of apoptosis by annexin binding
Exposure of phosphatidylserine at the outer plasma cell membrane of apoptotic cells was quantified by surface annexin V staining as described. 23 Briefly, one million cells were incubated for 48 h with the substances to be studied. Cells were then washed in phosphate-buffered saline (PBS), were resuspended in 200 l binding buffer (10 mmol/l Hepes, pH 7.4, 2.5 mmol/l CaCl 2 , 140 mmol/l NaCl) and were incubated with 0.5 g/ml of annexin V-fluorescein isothiocyanate (FITC; Bender MedSystem, Vienna, Austria) for 15 min in the dark. Cells were washed again, were resuspended in binding buffer and propidium iodide (PI, 5 g/ml) was added. Samples were analyzed by a FACSCalibur (Becton Dickinson, Heidelberg, Germany). For the determination of CD19 and CD5 expression cells were labeled with either a FITC-or PE-labeled antibody (Becton Dickinson). Data were analyzed using FlowJo software (Version 2.7.8).
Bcl-X analysis
One million cells were fixed using a commercially available Fix and Perm kit (Caltag, Burlingame, CA, USA), washed in PBS and centrifuged at 300 g for 5 min. The pelleted cells were resuspended in permeabilization solution and incubated with 10 l of anti-Bcl-XL (clone 7B2.5; epitope Bcl-XS; Southern Biotechnology Associates, Birmingham, AL, USA) or isotype-negative control (clone B 10; Southern Biotechnology Associates). The cells were washed, centrifuged at 300 g for 5 min and resuspended in 0.5 ml of 1% paraformaldehyde. All samples were studied using a FACS Calibur (Becton Dickinson). Data were analyzed using FlowJo software (Version 2.7.8).
Western blot
Cells were lysed in 10 mmol/l TRIS-HCl, pH 7.4, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 0.1% Triton-x 100, 1 M aprotinine and 0.1 mM phenylmethylsulfonyl fluoride. Protein concentrations were adjusted using a colorimetric assay. Proteins were separated by gel electrophoresis and transferred to a nitrocellulose membrane (Millipore, Eschborn, Germany). The transfer buffer contained 14.4 g glycine, 3 .03 g TRIS, and 20% methanol per 1000 ml. The membrane was blocked with PBS containing 3.5% dried milk and 0.1% Tween 20 (PBS/Tween). After washing three times with PBS/Tween, the membranes were incubated with anti-Bcl-2 at a dilution of 1:1000 (clone ⌬C 21; Santa Cruz Biotechnology, Heidelberg, Germany) or anti-Bax at a dilution of 1:1000 (clone N-20; Santa Cruz Biotechnology) and were visualized by autoradiography using the ECL detection kit (Amersham Pharmacia Biotech, Freiburg, Germany).
Caspase 3 colorimetric assay
Caspase 3 activity was determined following the instructions of the commercial caspase 3 colorimetric assay (R&D Systems, Minneapolis, MN, USA). As suggested by the manufacturer, caspase 3 activity is expressed as fold increase in caspase activity over that of control cells.
DNA fragmentation gel
Twenty × 10 6 cells were washed with PBS and lysed in 0.1 M EDTA (pH 8.0), 0.01 M TRIS-HCl (pH 7.6), 0.02 M NaCl. Fifty mM sodium acetate and 0.1 mg/ml proteinase K (Roche-Diagnostics, Mannheim, Germany) was added and incubated at 50°C for 5 h. One-fold volume phenol/chloroform/ isoamylalcohol (25:24:1; Roth, Karlsruhe, Germany) was added, mixed and centrifuged for 5 min at 12 000 r.p.m. The upper aqueous layer was transferred to a new microcentrifuge tube and 1 ml of cold isopropanol was added and incubated for 1 h at −70°C. After centrifugation the supernatant was decanted and the pellet was rinsed with 70% cold ethanol. After centrifugation and decanting of the supernatant the pellet was dissolved in H 2 O. Ten to 15 g DNA were separated in a 1.8% agarose gel. The DNA was visualized by UV illumination after ethidium bromide staining.
Statistical analysis
All data are expressed as means ± s.e.m. Statistical significance of differences between treatment and control groups was determined by a factorial ANOVA and a BonferroniDunn procedure as post-hoc test. Differences were considered statistically significant for P Ͻ 0.05. Statistical analysis was performed using Stat-View 4.51 software (Abacus Concepts, Calabasas, CA, USA).
Results
Rolipram enhances fludarabine-induced apoptosis in B-CLL cells
To investigate the potency of rolipram alone or in combination with fludarabine or mitoxantrone, freshly isolated B-CLL cells were incubated in the presence or absence of the different agents for 48 h. We first confirmed the previously described dose-dependent induction of apoptosis by rolipram (Figure 1 
Rolipram induces pro-apoptotic and suppresses antiapoptotic members of the Bcl-2 family
Bcl-2 is highly expressed in B-CLL cells contributing to the inhibition of apoptosis. However, not the expression of only one anti-apoptotic protein seems to determine apoptosis but the balance or disbalance of several pro-and anti-apoptotic members of the Bcl-2 family. Flow cytometry or Western blot analysis was performed to determine Bcl-2 and Bcl-X expression as members of the anti-apoptotic family and Bax expression as a member of the pro-apoptotic family.
The expression of the anti-apoptotic protein Bcl-X was dose dependently suppressed in the presence of rolipram. Figure  4a shows one representative flow cytometric analysis out of four performed. Figure 4b demonstrates the MFI ± s.e.m. of these four independent experiments studying B-CLL cells of four different patients. The maximal MFI of 11.4 ± 2.2 could be reduced to 4.6 ± 0.3 in the presence of 10 M rolipram (n = 4, P = 0.027). 
Rolipram-induced apoptosis is caspase-dependent
Apoptosis of B-CLL cells by rolipram has been shown to correlate with intracellular cAMP concentrations. 16 However, it remains elusive as to which apoptosis pathway is activated by rolipram. To evaluate the role of caspase-mediated apoptosis, isolated B-CLL cells were coincubated with increasing concentrations of rolipram in the presence or absence of the pancaspase inhibitor zVAD-fmk. Apoptosis was determined by annexin-V positivity by flow cytometry after a 24 h incubation ( Figure 6A ). In order to evaluate whether the caspase inhibitor is sufficiently inhibiting caspase activity, the caspase 3 activity was determined as described in the Methods section ( Figure  6b ). As shown in Figure 6a , in the absence of zVAD-fmk, apoptosis was induced dose dependently. However, in the presence of 50 M zVAD-fmk apoptosis induction could Leukemia almost completely be attenuated, comparing 12.5 ± 2.2% annexin V + in the absence of rolipram, vs 14.8 ± 3.0% annexin V + in the presence of 1 M rolipram and 14.6 ± 1.9% annexin V + in the presence of 10 M rolipram. When the concentration of zVAD-fmk was further increased to 200 M, apoptosis induction was further suppressed below spontaneous occurring apoptosis in untreated cells. In agreement with theses findings was the caspase 3 activity determined. In the absence of zVAD-fmk rolipram dose dependently increased the caspase 3 activity from 1.0 ± 0.2 relative caspase activity without rolipram vs 1.3 ± 0.2 relative caspase activity in the presence of 1 M rolipram and 1.9 ± 0.3 relative caspase activity (P Ͻ 0.05 vs control) in the presence of 10 M rolipram. In the presence of 50 M zVAD-fmk increasing concentrations of rolipram still resulted in a small increase of caspase 3 activity while in the presence of 200 M zVAD-fmk the caspase 3 activity determined was below the caspase 3 activity measured in the control cells. Interestingly, when apoptosis induction was analyzed in the same samples after 48 h incubation the presence of increasing concentrations of rolipram resulted in increased apoptosis and increased caspase 3 activity suggesting a loss of activity of zVAD-fmk after 24 h incubation in our experimental setting (data not shown as figure) . 
Discussion
In the present study we were able to demonstrate for the first time an enhancing effect of the PDE type 4 inhibitor rolipram on fludarabine-induced apoptosis in freshly isolated human B-CLL cells. Apoptosis was determined by annexin V positivity and PI uptake in flow cytometry and by DNA fragmentation. As a possible mechanism we could show a dose-dependent suppression of the anti-apoptotic proteins Bcl-X and Bcl-2 by rolipram and fludarabine by flow cytometry or by Western blot analysis. There was a dose-dependent increase of the proapoptotic protein Bax as evaluated by Western blot analysis. Both effects shift the balance of the members of the Bcl-2 family towards an increased susceptibility to apoptosis. Rolipraminduced apoptosis was in parallel with increased caspase 3 activity and was completely suppressed in the presence of the pan-caspase inhibitor zVAD-fmk.
The broad-spectrum phosphodiesterase inhibitor theophylline has been shown to induce apoptosis in B-CLL cells in vitro and to exert some beneficial effect in vivo as currently evaluated in clinical trials.
12-14 A more specific therapeutic strategy would be to take advantage of the preferential expression of the PDE subtypes PDE 1B1, PDE 4A and PDE 4B in B-CLL cells. 16 Kim and Lerner 16 observed a dose-dependent induction of apoptosis by the specific PDE 4 inhibitor rolipram. Because of its high specificity rolipram leads to a 300-fold stronger induction of apoptosis than theophylline (Ref. 12 and this paper, also Refs 14, 16) . This corresponds to earlier investigations by our group comparing rolipram and theophylline in suppression of tumor necrosis factor-␣ synthesis. 24, 25 Rolipram is widely used as a reference agent for PDE 4 inhibitors in in vitro experiments. It was evaluated in clinical trials in the 1980s as an antidepressant, when its clinical use was found to be limited by side-effects like nausea and emesis.
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Figure 4
Rolipram dose dependently inhibits Bcl-X expression in B-CLL cells. Mononuclear cells from patients with B-CLL were cultured in the presence of increasing concentrations of rolipram for 48 h. In the top panel the abscissa reflects Bcl-X expression and the ordinate cell counts. Bcl-X positivity was determined by isotype staining. Cells incubated with medium alone show a higher Bcl-X expression than cells incubated with rolipram. The flow cytometric analysis in the top panel is one representative experiment out of four different patient samples. A more detailed analysis is shown in the bottom panel, the asterisk (*) indicating a significant reduction in Bcl-X expression by 10 m rolipram (n = 4; P = 0.027).
However, there are currently several PDE 4 inhibitors under investigation in phase III clinical trials for the indications asthma and chronic obstructive pulmonary disease showing encouraging results and tolerable side-effects. 17, 27, 28 Even more remarkable is that the extent of rolipram-induced apoptosis is comparable to the apoptosis induced by fludarabine. We found that rolipram significantly enhanced fludarabine-induced apoptosis. For the combination of mitoxantrone and rolipram we could not detect an increase in apoptosis. It is not known in which way rolipram initiates the apoptotic pathway and whether there is a synergism with chemotherapeutic agents used in the treatment of B-CLL.
We subsequently investigated the mechanism by which rolipram induces apoptosis. We examined members of the Bcl-2 family as B-CLL cells have been consistently shown to contain high levels of the anti-apoptotic Bcl-2 protein. Several studies have correlated high Bcl-2/Bax ratios with diminished apoptotic responses to chemotherapy. [29] [30] [31] [32] [33] Consistent with its therapeutic effect fludarabine decreases Bcl-2 and Mcl-1 expression and increases Bax and p53 expression. 33, 34 In the present study, rolipram suppressed the expression of the antiapoptotic members of the Bcl-2 family Bcl-X and Bcl-2 and increased the expression of the pro-apoptotic member Bax, thereby shifting the balance of the Bcl-2 family towards the more pro-apoptotic side. At this point, we cannot exclude that the downregulation of Bcl-2 and Bcl-x is a consequence rather than the cause of apoptosis. The concomittant upregulation of Bax argues for the latter. In order to resolve this question further experiments are needed. We could not demonstrate an association between the expression of apoptosis-regulating proteins and Binet's stage. This is consistent with the findings described previously by Kitada and colleagues. 35 Our findings, that rolipram, which dose dependently increases intracellular cAMP levels induces apoptosis in resting B-CLL cells is in agreement with the literature. 9, 36, 37 This differs from reports concerning non-resting B cells, T cell hybridomas and T lymphoblasts, where the increase of cytosolic cAMP was associated with prevention of apoptosis. 38 ,39
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Figure 6
Rolipram-induced apoptosis is caspase-dependent. Mononuclear cells from patients with B-CLL were cultured in the presence of increasing concentrations of rolipram in the presence or absence of the pan-caspase-inhibitor zVAD-fmk for 24 h. Panel a represents annexin V positivity in the presence or absence of rolipram and the zVAD-fmk as indicated (n = 7). Panel b shows relative caspase 3 activity in the conditions indicated (n = 4). Bars represent means ± s.e.m.
The state of lymphocyte differentiation or activation may be a major determinant whether cAMP promotes survival or death.
To answer the question whether rolipram-induced apoptosis is caspase-mediated we incubated B-CLL cells with rolipram in the presence of the pan-caspase inhibitor zVADfmk, which has been utilized for this approach recently. 40 In the presence of zVAD-fmk the dose-dependent induction of apoptosis and caspase 3 activity by rolipram could be completely abrogated, indicating a caspase-dependent mechanism of rolipram-induced apoptosis in B-CLL cells.
In conclusion, since defective cell death mechanisms rather than dysregulation of cell cycle predominate in B-CLL, PDE 4 inhibitors as pro-apoptotic agents may provide a therapeutic principle either as a single therapy in early-stage patients or as combination therapy in advanced-stage patients with B-CLL.
